Applied Filters
Roche urges SCOTUS to cancel Illumina patent win
Roche has asked the US Supreme Court to declare that methods of separating DNA are not patent-eligible.
Ravgen and Myriad in patent dispute over DNA testing tech
Biotechnology company Ravgen has accused Myriad Genetics and Myriad Women’s Health of infringing two patents covering non-invasive DNA testing technology.
Eli Lilly seals $1bn genetics deal
Eli Lilly is expanding its genetics business with the $880 million purchase of Prevail Therapeutics, in a deal that could rise to more than $1 billion.
Illumina, Roche accused of infringing genetic testing patents
Pharmaceutical companies Illumina and Roche have been sued for allegedly infringing two patents covering the technology for non-invasive DNA testing by Maryland genetic testing company Ravgen.
Abbott must face HIV testing patent suit, rules judge
Abbott Laboratories must face allegations brought by Grifols Diagnostic and a Novartis subsidiary that its HIV testing products infringe a patent covering a method to create HIV proteins using recombinant DNA.
EPO reveals decision behind Broad patent revocation
The European Patent Office has released the long-awaited reasoning for its decision to uphold the revocation of a Broad Institute CRISPR/Cas9 patent. In January this year, the EPO’s Board of Appeal concluded that the Broad’s patent, EP2,771,468, lacked novelty due to an invalid claim to priority. The EPO dealt with three questions in its reasoning.
Bayer to spend up to $4bn on Asklepios BioPharmaceutical
Germany-based Bayer will pay up to $4 billion to acquire gene therapy company Asklepios BioPharmaceutical.
DNA start-up refused UK trademark
An Australian personalised genomics company has failed in its effort to obtain protection for its ‘MyDNA.life’ trademark in the UK.
Australian court rejects cattle genome patent appeal
The Federal Court of Australia has refused to block a cattle genome patent from the US, dismissing an appeal from Meat and Livestock Australia.
ERS Genomics appoints vice-president of IP
ERS Genomics, the company that provides access to CRISPR/Cas9 IP owned by researcher Emmanuelle Charpentier, has appointed Michael Arciero as vice-president of IP and commercial development.
